Lexeo Therapeutics Inc (NASDAQ: LXEO) kicked off on Monday, down -9.69% from the previous trading day, before settling in for the closing price of $10.01. Over the past 52 weeks, LXEO has traded in a range of $1.45-$11.72.
Annual sales at Healthcare sector company slipped by -99.98% over the past five years. While this was happening, its average annual earnings per share was recorded 18.77%. With a float of $45.32 million, this company’s outstanding shares have now reached $54.00 million.
Lexeo Therapeutics Inc (LXEO) Insider Updates
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Lexeo Therapeutics Inc is 16.08%, while institutional ownership is 78.63%. The most recent insider transaction that took place on Oct 17 ’25, was worth 34,767. In this transaction Chief Development Officer of this company sold 3,888 shares at a rate of $8.94, taking the stock ownership to the 65,862 shares. Before that another transaction happened on Oct 17 ’25, when Company’s Chief Legal Officer sold 3,526 for $8.94, making the entire transaction worth $31,530. This insider now owns 68,930 shares in total.
Lexeo Therapeutics Inc (LXEO) Performance Highlights and Predictions
In the latest quarterly report, which was put into the public domain on 9/30/2024, the organization reported -0.89 earnings per share (EPS), lower than consensus estimate (set at -0.67) by -0.22. Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.42 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 18.77% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 15.54% during the next five years compared to -99.98% drop over the previous five years of trading.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Trading Performance Indicators
Take a look at Lexeo Therapeutics Inc’s (LXEO) current performance indicators. Last quarter, stock had a quick ratio of 4.43.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -3.26, a number that is poised to hit -0.52 in the next quarter and is forecasted to reach -2.00 in one year’s time.
Technical Analysis of Lexeo Therapeutics Inc (LXEO)
Lexeo Therapeutics Inc (NASDAQ: LXEO) saw its 5-day average volume 1.37 million, a positive change from its year-to-date volume of 0.74 million. As of the previous 9 days, the stock’s Stochastic %D was 48.66%.
During the past 100 days, Lexeo Therapeutics Inc’s (LXEO) raw stochastic average was set at 80.24%, which indicates a significant increase from 28.72% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 0.72 in the past 14 days, which was higher than the 0.43 volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $6.95, while its 200-day Moving Average is $4.61. Nevertheless, the first resistance level for the watch stands at $9.36 in the near term. At $9.69, the stock is likely to face the second major resistance level. The third major resistance level sits at $9.98. If the price goes on to break the first support level at $8.75, it is likely to go to the next support level at $8.46. Assuming the price breaks the second support level, the third support level stands at $8.14.
Lexeo Therapeutics Inc (NASDAQ: LXEO) Key Stats
The company with the Market Capitalisation of 488.17 million has total of 54,001K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -98,330 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -26,100 K.
